Tiziana Life Sciences - Scheme Effective Date
20 Outubro 2021 - 10:40AM
Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) ("
Old
Tiziana") a biotechnology company focused on innovative
therapeutics for oncology, inflammation, and infectious diseases
announced on 20 August 2021 that it had formally commenced its
strategic plan to change its corporate structure by establishing
Tiziana Life Sciences Ltd (“
New Tiziana”), a
Bermuda-incorporated company, as the ultimate parent company of the
Tiziana Group. The reorganisation will be achieved by a scheme of
arrangement under Part 26 of the Companies Act 2006 (the
"
Scheme").
A Scheme Document setting out full details of
the Scheme (the "Scheme Document") was posted to
the shareholders of Old Tiziana on 3 September 2021.
Capitalised terms defined in the Scheme Document
shall, unless the context provides otherwise, have the same
meanings in this announcement.
Old Tiziana announces that the order of the
Court sanctioning the Scheme and confirming the Old Tiziana
Reduction of Capital have been delivered to the Registrar of
Companies today.
The Scheme and the Old Tiziana Reduction of
Capital are therefore effective today. The Scheme Record Time is
6:00 p.m. (London time) today. The last day of dealings in Old
Tiziana Shares is today and the Old Tiziana Shares will be delisted
tomorrow from the Main Market. It is expected that, following the
implementation of the Share Capital Consolidation (at a ratio of
two-for-one), the New Tiziana Shares will commence trading on
NASDAQ on 21 October 2021.
For the purposes of UK MAR, the person
responsible for arranging for the release of this announcement on
behalf of Old Tiziana is Dr Kunwar Shailubhai, Chief Executive
Officer.
For further information please
contact:
Keeren Shah, Finance Director: +44 (0) 207 495 2379
or email: info@tizianalifesciences.com
About Tiziana Life
SciencesTiziana Life Sciences plc is a dual listed
(NASDAQ: TLSA & UK LSE: TILS) biotechnology company that
focuses on the discovery and development of novel molecules to
treat human diseases in oncology, inflammation and infectious
diseases. In addition to Milciclib, the Company will be shortly
initiating Phase 2 studies with orally administered Foralumab for
Crohn's Disease and nasally administered Foralumab for progressive
multiple sclerosis. Foralumab is the only fully human anti-CD3
monoclonal antibody ("mAb") in clinical development in the world.
This Phase 2 compound has potential application in a wide range of
autoimmune and inflammatory diseases, such as Crohn's Disease,
multiple sclerosis, type-1 diabetes ("T1D"), inflammatory bowel
disease ("IBD"), psoriasis and rheumatoid arthritis, where
modulation of a T-cell response is desirable. The Company is
accelerating development of anti-Interleukin 6 receptor ("IL6R")
mAb, a fully human monoclonal antibody for treatment of IL6-induced
inflammation, especially for treatment of COVID-19 patients.
Forward looking statements
This announcement may contain certain
forward-looking statements. These forward-looking statements
include all matters that are not historical facts. These
forward-looking statements involve risks and uncertainties that
could cause the actual results of operations, financial condition,
prospects and the development of the sector in which Old Tiziana
operates to differ materially from the impression created by these
forward-looking statements. Old Tiziana does not undertake any
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
Do not place undue reliance on forward-looking statements, which
speak only as of the date of this announcement.
Tiziana Life Sciences (NASDAQ:TLSA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Tiziana Life Sciences (NASDAQ:TLSA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024